Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

NCT02145637 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Afatinib plus Ruxolitinib combination therapy

Sponsor

Yonsei University